This review identifies the current literature on the use of bevacizumab for cerebral radiation
necrosis in patients with high-grade gliomas, summarizes the clinical course and …

Background Cerebral radiation necrosis is a serious complication of radiation treatment for
brain tumors. Therapeutic options include corticosteroids, anticoagulation and hyperbaric …

Background: Cerebral radiation necrosis (RN) is a devastating complication of radiation
therapy for brain tumors. Recent studies have explored the role of bevacizumab, a …

Bevacizumab is expected to constitute a new treatment modality for radiation necrosis. In the
present cases, we observed a recurrence of radiation necrosis after temporary improvement …

Radiation necrosis is a devastating complication following radiation to the central nervous
system. The purpose of this study was to perform a comprehensive analysis of cases in the …

PURPOSE: Reirradiation is a treatment option for recurrent high-grade glioma with proven
but limited effectiveness. Therapies directed against vascular endothelial growth factor have …

Bevacizumab is one of the rare drugs that could improve high-grade glioma outcome after
failure of chemoradiotherapy. However, to date, there is no biomarker predictive for efficacy …

Angiogenesis has recently become a major target for the development of new antineoplastic
drugs. The most serious adverse events linked to angiogenesis inhibitors are venous or …

Background Radiation brain necrosis (RBN) is a serious complication in patients receiving
radiotherapy for intracranial disease. Many studies have investigated the efficacy and safety …

Bevacizumab and irinotecan are effective against recurrent malignant gliomas. However, at
subsequent progression, patients rarely respond to a second bevacizumab-containing …